Report cover image

Type 4 cyclic nucleotide phosphodiesterase inhibitors - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 70 Pages
SKU # DEL18678409

Description

Type 4 cyclic nucleotide phosphodiesterase inhibitors - Pipeline Insight, 2024



DelveInsight’s, “Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Understanding

Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors: Overview

Cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolytic destruction of the intracellular second messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), to produce 5’-AMP and 5’-GMP, respectively. Type 4 cyclic nucleotide phosphodiesterases (PDE4) are a family of low km 3',5'-cyclic adenosine monophosphate (cAMP)-specific phosphodiesterases including at least 20 isozymes encoded by four genes (PDE4A, PDE4B, PDE4C, and PDE4D) in mammals. Because PDE4 isoforms exhibit widespread tissue distribution, perhaps more than any other PDE family, inhibition of PDE4 enzymes alters cAMP-signaling in many cells. The development of PDE4 inhibitors with improved therapeutic indexes has been a major focus of pharmaceutical research for the treatment of chronic inflammatory diseases.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors R&D. The therapies under development are focused on novel approaches for Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors.
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Emerging Drugs Chapters

This segment of the Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Emerging Drugs
  • Ensifentrine : Verona Pharma
Ensifentrine is an inhaled, first-in-class dual inhibitor of phosphodiesterase 3 (PDE3) and 4 (PDE4). The drug is in Phase III clinical studies for the treatment of chronic obstructive pulmonary disease and in Phase II developmental studies for asthma and cystic fibrosis treatment. In April 2021, Verona Pharma has reported positive data from a pilot study evaluating a pressurised metered-dose inhaler (pMDI) formulation of ensifentrine to treat Covid-19.
  • Difamilast: Otsuka Pharmaceutical
Difamilast is an investigational non-steroidal topical anti-inflammatory PDE4 inhibitor. The drug is in development for the treatment of mild to moderate atopic dermatitis. Medimetriks has sole exclusive U.S rights to develop and commercialize MM36 (difamilast). In September 2020, Otsuka Pharmaceutical announced that an application has been submitted to the Pharmaceuticals and Medical Devices Agency in Japan to seek manufacturing and marketing approval for difamilast (OPA-15406) in patients with atopic dermatitis.

Further product details are provided in the report……..

Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors
There are approx. 20+ key companies which are developing the Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors. The companies which have their Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drug candidates in the most advanced stage, i.e. Preregistration include, Otsuka Pharmaceutical.
  • Phases
DelveInsight’s report covers around 20+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drugs.

Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Report Insights
  • Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drugs?
  • How many Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Verona Pharma
  • MediciNova
  • Innovation Pharmaceuticals
  • Otsuka Pharmaceutical
  • Chiesi Farmaceutici
  • BioTheryX
  • AnnJi Pharmaceutical
  • UNION Therapeutics
  • MediciNova
  • Amgen
  • Arcutis Biotherapeutics
Key Products
  • Ensifentrine
  • Ibudilast
  • Brilacidin
  • Difamilast
  • Tanimilast
  • BTX-2640
  • AJ-503
  • Research programme: phosphodiesterase type 4 inhibitors
  • Tipelukast
  • Apremilast
  • Roflumilast topical

Table of Contents

70 Pages
Introduction
Executive Summary
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Ensifentrine: Verona Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tanimilast: Chiesi Farmaceutici
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BTX-2640: BioTheryX
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Key Companies
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Key Products
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors- Unmet Needs
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors- Market Drivers and Barriers
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors- Future Perspectives and Conclusion
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Analyst Views
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us